Methadone initiation and rotation in the outpatient setting for patients with cancer pain

Cancer

Volumn 116, Issue 2, 2010, Pages 520-528

  Parsons, Henrique A ^a   De La Cruz, Maxine ^a   El Osta, Badi ^a   Li, Zhijun ^a   Calderon, Bianca ^a   Palmer, J Lynn ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Methadone; Neoplasms; Outpatients; Pain; Palliative care

Indexed keywords

METHADONE;

ADULT; AGED; ARTICLE; CANCER PAIN; CONSTIPATION; CONTROLLED STUDY; DELIRIUM; FEMALE; FOLLOW UP; HALLUCINATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYOCLONUS; NAUSEA; OUTPATIENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME;

AMBULATORY CARE; ANALGESICS, OPIOID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NEOPLASMS; PAIN; PALLIATIVE CARE; TREATMENT OUTCOME;

EID: 75649088133     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24754     Document Type: Article

References (48)

1. Goudas LC, Bloch R, Gialeli-Goudas M, Lau J, Carr DB. The epidemiology of cancer pain. Cancer Invest. 2005;23: 182-190.
2. Cancer Pain Relief. Geneva, Switzerland: World Health Organization; 1986.
3. Bruera E, MacMillan K, Hanson J, MacDonald RN. Palliative care in a cancer center: results in 1984 versus 1987. J Pain Symptom Manage. 1990;5:1-5.
4. Lotsch J. Opioid metabolites. J Pain Symptom Manage. 2005;29(5 suppl):S10-S24.
5. Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer. 2001;9:73-83.
6. Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol. 1999;17:3307-3312.
7. Vigano A, Fan D, Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain. 1996;67:115-119.
8. Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol. 2001;19:2898-2904.
9. Shaiova L, Berger A, Blinderman CD, et al. Consensus guideline on parenteral methadone use in pain and palliative care. Palliat Support Care. 2008;6:165-176.
10. Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol. 2004;22: 185-192.
11. Mercadante S, Porzio G, Ferrera P, et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain. 2008; 12:1040-1046.
12. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004;76:250-269.
13. Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 2000;92:1392-1399.
14. Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. Effects of methadone on QT-interval dispersion. Pharmacotherapy. 2005;25:1523-1529.
15. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol. 2005;95: 915-918.
16. Hagen NA, Wasylenko E. Methadone: outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage. 1999;18:369-375.
17. Hernansanz S, Gutierrez C, Rubiales AS, Flores LA, del Valle ML. Opioid rotation to methadone at home. J Pain Symptom Manage. 2006;31:2-4.
18. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med. 2002;5:127-138.
19. Fainsinger RL, Nekolaichuk CL. A "TNM" classification system for cancer pain: the Edmonton Classification System for Cancer Pain (ECS-CP). Support Care Cancer. 2008;16: 547-555.
20. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7:6-9.
21. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000;88:2164-2171.
22. Reddy SK. Pain Management. In: Elsayem A, Driver L, Bruera E, eds. The M. D. Anderson Symptom Control and Palliative Care Handbook. 2nd ed. Houston, TX: M. D. Anderson Cancer Center; 2004:38.
23. Ripamonti C, De Conno F, Groff L, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of 2 clinical experiences. Ann Oncol. 1998;9:79-83.
24. Walker PW, Palla S, Pei BL, et al. Switching from methadone to a different opioid: what is the equianalgesic dose ratio? J Palliat Med. 2008;11:1103-1108.
25. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage. 2001;22:672-687.
26. Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer. 1998;82:1167-1173.
27. Oneschuk D, Bruera E. Respiratory depression during methadone rotation in a patient with advanced cancer. J Palliat Care. 2000;16:50-54.
28. Watanabe S, Tarumi Y, Oneschuk D, Lawlor P. Opioid rotation to methadone: proceed with caution. J Clin Oncol. 2002;20:2409-2410.
29. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004;(3): CD004847.
30. Mancini I, Lossignol DA, Body JJ. Opioid switch to oral methadone in cancer pain. Curr Opin Oncol. 2000;12:308-313.
31. Bruera E, Watanabe S, Fainsinger RL, Spachynski K, Suarez-Almazor M, Inturrisi C. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain. 1995;62:141-146.
32. Morley JS, Watt JW, Wells JC, Miles JB, Finnegan MJ, Leng G. Methadone in pain uncontrolled by morphine. Lancet. 1993;342:1243.
33. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol. 1998;16:3216-3221.
34. Tse DM, Sham MM, Ng DK, Ma HM. An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliat Med. 2003;17:206-211.
35. Mercadante S, Casuccio A, Agnello A, Serretta R, Calderone L, Barresi L. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol. 1998;16:3656-3661.
36. De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V, Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol. 1996;14:2836-2842.
37. Daeninck PJ, Bruera E. Reduction in constipation and laxative requirements following opioid rotation to methadone: a report of 4 cases. J Pain Symptom Manage. 1999;18:303-309.
38. Kharasch ED, Bedynek PS, Park S, Whittington D, Walker A, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther. 2008;84:497-505.
39. Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology. 2009;110:660-672.
40. Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004;50:551-559.
41. Haddad A, Davis M, Lagman R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer. 2007;15:251-257.
42. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 1999;354:1625-1633.
43. Fredheim OM, Borchgrevink PC, Hegrenaes L, Kaasa S, Dale O, Klepstad P. Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: a prospective 9-month follow-up study. J Pain Symptom Manage. 2006;32:180-185.
44. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003;289:2120-2127.
45. Benitez-Rosario MA, Salinas-Martin A, Aguirre-Jaime A, Perez-Mendez L, Feria M. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio-predicting factors. J Pain Symptom Manage. 2009;37:1061-1068.
46. Watanabe S, Belzile M, Kuehn N, Hanson J, Bruera E. Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations. Cancer Treat Rev. 1996;22(suppl A):131-136.
47. Dickerson ED. Methadone: the question or the answer for US opioid therapy and pharmaco-economics? Support Care Cancer. 2001;9:646-648.
48. Parsons HA, Shukkoor A, Quan H, et al. Intermittent subcutaneous opioids for the management of cancer pain. J Palliat Med. 2008;11:1319-1324.